Transcode Therapeutics: Funding, Investors & Team (Sep 2026)
TransCode Therapeutics is an emerging RNA oncology company committed to defeating cancer through the intelligent design and effective delivery of RNA therapeutics. Our lead therapeutic candidate, that we believe has blockbuster potential, targets an RNA molecule which has been shown to be the driver of metastatic disease across multiple tumor types and has been validated pre-clinically in our lab at MGH. Our initial FIH clinical study, for which an eIND filing is planned for Q1 of 2022, is intended to provide positive proof-of-mechanism for the TTX platform.
Transcode Therapeutics has raised $9.4M across 3 funding rounds on record, the most recent an undisclosed round of $6.0M announced in Apr 2026.
That round is below the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Transcode Therapeutics Company Profile and Key Stats
Latest funding round on record: Apr 2026.
Transcode Therapeutics Funding Rounds
Transcode Therapeutics raised $2.3M in a Grant announced in Aug 2021.
10 months later, a Grant of $1.1M was announced in Jun 2022.
3.8 years later, an undisclosed round of $6.0M was announced in Apr 2026.
Transcode Therapeutics Founders and Leadership Team
Contact details for the Transcode Therapeutics team: 2 of 2 have an email address on file.
Start 14-day free trial →Transcode Therapeutics Funding Compared to Other Biotechnology Startups
Transcode Therapeutics' latest round of $6.0M is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Transcode Therapeutics in Biotechnology and Boston
Companies Similar to Transcode Therapeutics
Superluminal Medicines is a biotech company that specializes in rapidly developing new drugs through a…
Senticell's mission is to fully harness the unique immune and genetic functions of RBC to transform and treat…
ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a…
EIT Pharma is a commercial-stage biotechnology company focuses on developing and commercializing…
Halia Therapeutics is a biopharmaceutical company in the preclinical stage that is developing new treatments…
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Transcode Therapeutics Funding FAQs
What does Transcode Therapeutics do?
TransCode Therapeutics is an emerging RNA oncology company committed to defeating cancer through the intelligent design and effective delivery of RNA therapeutics. Our lead therapeutic candidate, that we believe has blockbuster potential, targets an RNA molecule which has been shown to be the driver of metastatic disease across multiple tumor types and has been validated pre-clinically in our lab at MGH. Our initial FIH clinical study, for which an eIND filing is planned for Q1 of 2022, is intended to provide positive proof-of-mechanism for the TTX platform.
How much funding has Transcode Therapeutics raised?
Transcode Therapeutics has raised $9.4M across 3 rounds on record. The most recent is an undisclosed round of $6.0M announced in Apr 2026.
When did Transcode Therapeutics last raise funding?
Transcode Therapeutics' most recent funding round on record is an undisclosed round of $6.0M, announced in Apr 2026.
Who founded Transcode Therapeutics?
FundedIQ lists Philippe Calais (Founder) at Transcode Therapeutics.
Who is the CEO of Transcode Therapeutics?
Michael Dudley is listed as CEO at Transcode Therapeutics.
Where is Transcode Therapeutics headquartered?
Transcode Therapeutics is based in Boston, Massachusetts, United States.
How many employees does Transcode Therapeutics have?
Transcode Therapeutics is in the 1-10 employee band.
How does Transcode Therapeutics' funding compare to other Biotechnology startups?
Transcode Therapeutics' latest round of $6.0M is below the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.
About FundedIQ's Transcode Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Transcode Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.